Answers are grounded in this paper and cite their sources.
Background. A biomarker would be valuable in the diagnosis, risk stratification and prognosis of patients with traumatic brain injury (TBI).Methods. We measured serum levels of S-100β, neuron specific enolase (NSE) and myelin basic protein (MBP) in 50 TBI subjects, and 50 age and gender matched controls. Patients were recruited within 6 hours of the initial injury, they had an initial Glasgow Coma Scale (GCS) score of 14 or less, or a GCS score of 15 with witnessed loss of consciousness (LOC) or amnesia.Results. S-100β, NSE and MBP levels were significantly higher in TBI subjects than in control subjects ( P<0.001 for S-100β and NSE; P=0.009 for MBP). Initial S-100β levels were significantly higher in TBI subjects who had not retuned to normal activities 2 weeks following their injury than in TBI subjects who had retuned to normal activities ( P=0.022 ). MBP levels were higher in TBI subjects with positive findings on the baseline CT scan than in CT-negative subjects ( P=0.007 ).Conclusions. S-100β, NSE and MBP may be present in the sera of TBI subjects in elevated quantities relative to controls. S-100β may aid in predicting short-term outcome in TBI subjects.
No takes yet. Share an insight, caveat, or question.
Borg et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: